Levocetirizine

The reviewed current Xyzal prescription PI indicates perennial allergic-rhinitis symptom relief in children 6 months to 2 years, and uncomplicated chronic idiopathic urticaria skin manifestations in adults and children age 6 months and older. Its formal indication section does not list adult perennial or seasonal rhinitis, even though older trials and broader FDA safety summaries discuss allergy treatment. Preserve the current product-specific indication wording.

Selected OTC tablets and solution temporarily relieve runny nose, sneezing, itchy/watery eyes, and itchy nose/throat due to hay fever or other respiratory allergies. Tablets begin at age 6; the selected OTC liquid begins at age 2. Prescription infant treatment is not an OTC infant self-use authorization. OTC Drug Facts does not supply a chronic-hives treatment indication.

Treatment is symptomatic and should match diagnosis, age and kidney function. The current labeled schedules do not establish an anaphylaxis rescue regimen, universal escalation above 5 mg/day, or treatment for every cause of itching. New or persistent symptoms, urinary issues and severe discontinuation itching require clinical evaluation.

For chronic idiopathic urticaria, adults/children age 12+ use 5 mg once each evening; 2.5 mg may adequately control some patients. Children 6–11 use 2.5 mg each evening, maximum 2.5 mg/day. Children 6 months–5 years use 1.25 mg each evening, maximum 1.25 mg/day. For the current prescription perennial-rhinitis indication at 6 months–2 years, use 1.25 mg each evening and do not exceed it. Tablets are scored for a 2.5 mg half-tablet; use solution for 1.25 mg. Food does not require a dose-timing restriction.

The label uses creatinine clearance in mL/min, not a universal interchangeable eGFR value. Renal categories/ranges below reproduce its wording; shared endpoints at 30 and 50 mL/min are not silently reassigned. At an exact boundary, confirm the clinician’s chosen category. Children 6 months–11 years with impaired renal function are contraindicated, so this table cannot be applied to them.

Adults/children 12–64 may take one 5 mg tablet each evening (half 2.5 mg may suffice for milder symptoms), or 5–10 mL of selected 0.5 mg/mL liquid depending on symptom severity; maximum 5 mg/24 hours. Children 6–11 take half a 5 mg tablet or 5 mL solution each evening, maximum 2.5 mg/24 hours. The selected liquid permits children 2–5 to take 2.5 mL each evening, maximum 1.25 mg/24 hours. Tablets must not be used under 6, and OTC liquid must not be used under 2. Age 65+ requires asking a doctor; consumers with kidney disease must not use these OTC products.

No adjustment is needed for solely hepatic impairment; with combined renal/hepatic impairment, adjust according to renal function within the permitted age group. Use a calibrated measuring device and confirm the concentration; OTC liquid specifies its enclosed dosing cup. Do not exceed the applicable daily dose or import adult renal schedules into children.

Prescription use is contraindicated with hypersensitivity to levocetirizine, cetirizine or product ingredients; end-stage renal disease with CrCl < 10 mL/min; hemodialysis; and renal impairment in children 6 months–11 years. OTC instructions are stricter for self-use: do not use with any kidney disease or prior allergy to the product/cetirizine. OTC tablet/liquid lower-age restrictions apply independently of prescription infant eligibility.

No formal boxed warning is present in the reviewed prescription Xyzal PI. Its serious warnings and FDA’s 2025 discontinuation-pruritus communication still require counseling; absence of a box does not mean freedom from sedation, retention, allergy or withdrawal-related itching.

Common adult/adolescent trial reports include somnolence, nasopharyngitis, fatigue, dry mouth and pharyngitis. Pediatric reports include fever, cough, somnolence, nosebleed, diarrhea or constipation, varying by age/study. Postmarketing reports include anaphylaxis/angioedema, urinary retention, seizures, mood/behavior changes, hepatitis and severe skin reactions; voluntary reports do not establish individual incidence or certain causation. Trial doses used for safety evaluation are not the same as approved pediatric dose ceilings.

Avoid concurrent alcohol or CNS depressants because alertness and coordination may worsen. Review sedatives, tranquilizers, sleep aids, opioids and other antihistamine products for overlapping effects and duplicate ingredients with a clinician/pharmacist. OTC labeling likewise warns that alcohol/sedatives/tranquilizers increase drowsiness.

No formal in-vivo interaction studies were performed with levocetirizine in the selected PI. Its interaction discussion uses racemic cetirizine studies: theophylline modestly reduced cetirizine clearance, and ritonavir increased cetirizine exposure. Those findings are not direct measured levocetirizine effect sizes or mandatory dose algorithms. Review the combination and monitor tolerability, especially if kidney function is reduced.

Less than 14% is metabolized and in-vitro data suggest low CYP interaction potential, but this does not prove every combination safe. Renal elimination and pharmacodynamic sedation remain important. Reassess dosing when renal function changes rather than automatically increasing the antihistamine for persistent symptoms.

Prescription CIU use begins at 6 months, with the reviewed PAR indication limited to 6 months–2 years. Recommended pediatric doses rely on adult efficacy extrapolation and pediatric exposure/safety comparisons; 5 mg in children 6–11 produces roughly twice adult exposure. Renal impairment at 6 months–11 years is a contraindication. Older adults need cautious selection and renal assessment; OTC age 65+ requires a doctor rather than automatic adult self-dosing.

Renal dysfunction markedly increases exposure and prolongs elimination, requiring reduced dose/frequency in eligible age 12+ patients. ESRD/hemodialysis precludes use; dialysis removes little drug and is not a dosing workaround. Isolated hepatic impairment does not require adjustment, but concomitant renal impairment does. No pediatric renal-adjustment table is provided because use is contraindicated in that impaired group.

Available human pregnancy data are insufficient to identify drug-associated risks; reassuring animal studies do not establish human safety. Prescription PI states that direct human milk/infant-effect/milk-production data for levocetirizine are absent, while cetirizine is reported in human milk, and recommends weighing breastfeeding benefits against maternal need and potential infant effects. Selected OTC labels instead state breastfeeding use is not recommended and advise pregnant users to ask a health professional. These are distinct product-label instructions, not a claim that every supervised lactation exposure is absolutely contraindicated.

Current NIH LactMed (September 2025) separately summarizes limited measured human milk data, unlike the selected PI’s no-data statement, and considers levocetirizine potentially acceptable during breastfeeding. It cautions that larger doses or prolonged use may cause infant drowsiness/other effects or reduce milk supply, especially with pseudoephedrine or before lactation is established. Discuss this evidence-label difference with a clinician and monitor infant feeding/alertness and milk supply; it does not override OTC self-use instructions or establish zero risk.

Levocetirizine is the pharmacologically active enantiomer of cetirizine. Selective H1-receptor inhibition explains antihistaminic symptom relief. In-vitro affinity comparisons do not establish a universal clinical superiority or justify exceeding labeled doses.

Adult tablet peak concentration occurs around 0.9 hour; solution peaks around 0.5 hour, and equal 5 mg doses are bioequivalent. Food delays tablet peak but does not reduce overall exposure. Protein binding is about 91–92%, adult half-life about 8–9 hours, and urinary elimination accounts for most administered drug/metabolites; glomerular filtration and tubular secretion are involved. Renal impairment increases exposure and half-life substantially.

Assess symptom benefit, drowsiness/functional impairment, urinary emptying, medicines/alcohol and renal function when impairment or older age makes dose selection relevant. The labels do not require routine liver tests or a fixed universal laboratory interval. Reassess continued need during chronic treatment and discuss rare severe itching after discontinuation rather than implying an evidence-based home taper.

Use the exact age/product dose, a calibrated liquid measure and the evening schedule. Do not give OTC products below their ages or self-use them with kidney disease. Seek urgent help for airway swelling/severe allergy or inability to urinate; obtain medical advice for severe itching after stopping. Suspected overdose requires poison-center/emergency guidance; adult drowsiness and initial pediatric agitation followed by drowsiness are reported, and no home dose-correction protocol is supplied.

The reviewed prescription PI describes white oval scored 5 mg Xyzal tablets with red Y markings and clear/colorless 0.5 mg/mL solution. Its body retains legacy Sanofi NDCs 0024-5803-90 and 0024-5804-05, while current Chattem SPL package records list 41167-5803-9 and 41167-5804-5. Verify the actual dispensed package; legacy appearance/NDC text is not proof of present stock. Selected OTC Xyzal Allergy 24HR tablets and Children’s Xyzal Allergy solution have separate Drug Facts.

Selected tablets contain 5 mg levocetirizine dihydrochloride and can supply 2.5 mg as a scored half-tablet. Selected prescription/OTC solutions contain 2.5 mg/5 mL = 0.5 mg/mL: 1.25 mg = 2.5 mL, 2.5 mg = 5 mL, 5 mg = 10 mL. These are oral products; cetirizine and combination cold/allergy products are not interchangeable ingredient identities.

Reviewed Rx products store at 20–25°C (68–77°F), with excursions 15–30°C permitted. Selected OTC tablets/solution specify 20–25°C and intact safety seals; do not use torn/open blister units or damaged/missing bottle inner seals. OTC liquid specifies its enclosed cup. Check the actual package, secure medicines from children, and avoid measuring with household spoons.